Document:

Exhibit 10.1

 

THIS WARRANT AND THE UNDERLYING SECURITIES
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR
SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE ACT OR UNLESS
SUCH TRANSACTION IS IN COMPLIANCE WITH APPLICABLE FEDERAL AND STATE SECURITIES LAWS.

 

NORTHWEST BIOTHERAPEUTICS, INC.

 

CLASS D-2 WARRANTS

 

	No.  WD2-	____________, 2017

 

This
Certifies That, for value received, ____________________________ or its assigns (the “Holder”),
is entitled to subscribe for and purchase from Northwest Biotherapeutics, Inc.,
a Delaware corporation, with its principal office in Bethesda, Maryland (the “Company”), such number
of Exercise Shares as provided herein at the Exercise Price as provided herein. This Class D-2 Warrant (the “Warrant”)
is being issued pursuant to the terms of that certain Subscription Agreement, dated __________, 2017, by and among the Company
and Holder (the “Agreement”).

 

1.            Definitions.
Capitalized terms used but not defined herein shall have the meanings set forth in the Agreement, as applicable. As
used herein, the following terms shall have the following respective meanings:

 

(a)          “Business
Day” means a day except a Saturday, a Sunday or other day on which commercial banks in the City of New York are authorized
or required by applicable law to be closed.

 

(b)          “Common
Stock” shall mean the common stock of the Company, par value $0.001 per share.

 

(c)          “Exercisability
Date” shall mean the date the Company provides written notice to the Holder that the Company’s certificate
of incorporation has been amended subsequent to the date hereof to increase the number of authorized shares of Common Stock thereunder
and that all other necessary corporate action has been taken to authorize and reserve for issuance the Exercise Shares; provided
that the Company shall provide such written notice within five Business Days after such amendment has been effected and all other
necessary corporate action has been taken.

 

(d)          “Exercise
Period” shall mean the period commencing on the Exercisability Date and ending two (2) years after the Exercisability
Date.

 

(e)          “Exercise
Price” of this Warrant shall be Thirty Cents ($0.30) per share.

 

    	 	1	 

     

    

 

(f)          “Exercise
Share” shall mean each of the fully paid and non-assessable shares of Common Stock for which this Warrant is exercisable
at the Exercise Price. The number of Exercise Shares initially shall be ____________________ (_____________).

 

2.             Exercise
of Warrant.

 

2.1           Vesting
and Exercise. This Warrant will be fully vested upon issuance, but will not be exercisable prior to the Exercisability Date.
Subject to the preceding limitation on exercise and the conditions set forth in this Warrant, the rights represented by this Warrant
may be exercised in whole or in part at any time or times prior to the expiration of the Exercise Period, by delivery of the following
to the Company at its address set forth above (or at such other address as it may designate by notice in writing to the Holder):

 

(a)          An
executed Notice of Exercise in the form attached hereto;

 

(b)          Payment
of the Exercise Price by wire transfer of immediately available funds, subject to Paragraph 2.2 below; and

 

(c)          This
Warrant.

 

Upon the exercise of
the rights represented by this Warrant, a certificate or certificates for the Exercise Shares so purchased, registered in the name
of the Holder or Holder’s designee(s), shall be issued and delivered to the Holder within a reasonable time after the rights
represented by this Warrant shall have been so exercised (but in no event less than three (3) Trading Days following the date of
exercise). In the event that this Warrant is being exercised for less than all of the then-current number of Exercise Shares purchasable
hereunder, the Company shall, concurrently with the issuance by the Company of the number of Exercise Shares for which this Warrant
is then being exercised, issue a new Warrant exercisable for the remaining number of Exercise Shares purchasable hereunder.

 

The person in whose
name any certificate or certificates for Exercise Shares are to be issued upon exercise of this Warrant shall be deemed to have
become the holder of record of such shares on the date on which this Warrant was surrendered and payment of the Exercise Price
was made, irrespective of the date of delivery of such certificate or certificates, except that, if the date of such surrender
and payment is a date when the stock transfer books of the Company are closed, such person shall be deemed to have become the holder
of such shares at the close of business on the next succeeding date on which the stock transfer books are open.

 

2.2           Net
(Cashless) Exercise. If and only if, and to the extent that, there is no effective registration statement registering the issuance
or resale of Common Stock of the Company upon exercise of this Warrant at the time this Warrant is exercised, and if the fair market
value of one Exercise Share is greater than the Exercise Price (at the date of calculation as set forth below), then in lieu of
exercising this Warrant by payment of cash, the Holder may elect to receive shares equal to the value (as determined below) of
this Warrant (or the portion thereof being canceled) by surrender of this Warrant at the principal office of the Company together
with the properly endorsed Notice of Exercise in which event the Company shall issue to the Holder a number of Exercise Shares
computed using the following formula:

 

    	 	2	 

     

    

 

 

		   Where X =	the number of Exercise Shares to be issued to the Holder

 

		Y =	the number of Exercise Shares purchasable under the Warrant or, if only a portion of the Warrant is being exercised, that portion
of the Warrant being canceled (at the date of such calculation)

 

		A =	the average of the VWAP of the Common Stock for the ten consecutive Trading Days ending on the Trading Day immediately prior
to the date of exercise of the Warrants

 

		B =	Exercise Price (as adjusted to the date of such calculation)

 

“Trading
Day” means a day on which (i) trading in Common Stock generally occurs on the principal U.S. national or regional
securities exchange on which the Common Stock is then listed or, if the Common Stock is not then listed on a U.S. national or regional
securities exchange, on the principal other market on which the Common Stock is then traded, which may be OTCQB or OTCQX (a “Trading
Market”) and (ii) a last reported sale price for our Common Stock is available on such securities exchange or market.
If the Common Stock is not so listed or traded, “Trading Day” means a “Business Day.”

 

“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding
date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading
Day from 9:30 a.m. (New York City time) to 4:00 p.m. (New York City time)), (b) if such volume weighted average price is unavailable
from Bloomberg L.P. or its successor, the closing sales price of the Common Stock on the Trading Market, or (c) in all other cases,
the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers
of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of
which shall be paid by the Company.

 

2.3           Securities
for Which Warrant is Exercisable.  Subject to the limitations on exercise and the conditions set forth in this Warrant, this
Warrant shall be exercisable, in whole or in part, and from time to time, for Common Stock of the Company.

 

3.             Covenants
of the Company.

 

3.1           Covenants
as to Exercise Shares. The Company covenants and agrees that all Exercise Shares that may be issued upon the exercise of the
rights represented by this Warrant will, upon issuance, be validly issued and outstanding, fully paid and non-assessable, and free
from all taxes, liens and charges with respect to the issuance thereof.

 

    	 	3	 

     

    

 

3.2           No
Impairment. The Holder’s rights, preferences and privileges granted under and/or in connection with this Warrant may
not be amended, modified or waived without the Holder’s prior written consent.

 

4.             Representations
of Holder.

 

4.1           Acquisition
of Securities for Personal Account. The Holder represents and warrants that the securities it is acquiring on the date hereof
are being acquired solely for its account for investment and not with a view to or for sale or distribution of such securities,
or any part thereof, except in compliance with applicable federal and state securities laws. The Holder also represents and warrants
that all of the legal and beneficial interests in the securities which the Holder is acquiring are being acquired for, and will
be held for, its account only.

 

4.2           Securities
Are Not Registered.

 

(a)          The
Holder understands that the Warrant and the Exercise Shares have not been registered under the Act on the basis that no distribution
or public offering of the Common Stock of the Company is to be effected by the Holder. The Holder realizes that the basis for the
exemption may not be present if, notwithstanding its representations, the Holder has a present intention of acquiring the securities
for a fixed or determinable period in the future, selling (in connection with a distribution or otherwise), granting any participation
in, or otherwise distributing the securities. The Holder represents and warrants that it has no such present intention.

 

(b)          The
Holder recognizes that the Warrant and the Exercise Shares must be held indefinitely unless they are subsequently registered under
the Act or an exemption from such registration is available.

 

(c)          The
Holder is aware that neither the Warrant nor the Exercise Shares may be sold pursuant to Rule 144 adopted under the Act unless
certain conditions are met, including, among other things, the availability of certain current public information about the Company,
the resale following the required holding period under Rule 144 and the number of shares being sold during any three month period
not exceeding specified limitations.

 

4.3           Disposition
of Warrant and Exercise Shares. The Holder understands and agrees that any Exercise Shares issued pursuant to exercise of this
Warrant will not be registered at the time of issuance, and all certificates evidencing the Shares to be issued to the Holder may
bear the following legend:

 

THESE SECURITIES HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED
OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES UNDER THE ACT OR UNLESS SUCH TRANSACTION
IS IN COMPLIANCE WITH APPLICABLE FEDERAL AND STATE SECURITIES LAWS.

 

    	 	4	 

     

    

 

4.4           Accredited
Investor Status. The Holder is an “accredited investor” as defined in Regulation D promulgated under the Act.

 

5.             Adjustment
of Exercise Price and Exercise Shares.

 

5.1          Changes
in Securities. In the event of changes in the Common Stock by reason of stock dividends, splits, recapitalizations, reclassifications,
combinations or exchanges of shares, separations, reorganizations, liquidations, or the like, the aggregate number of Exercise
Shares then available under the Warrant and the Exercise Price thereof shall be correspondingly adjusted to give the Holder of
the Warrant, on exercise for the same aggregate Exercise Price, the same shares as the Holder would have owned had the Warrant
been exercised prior to the event and had the Holder continued to hold such shares until after the event requiring adjustment.
The form of this Warrant need not be changed because of any adjustment in the number of Exercise Shares subject to this Warrant.
Notwithstanding anything in this Warrant to the contrary, no adjustment will be made to the Exercise Price of this Warrant, such
that the Exercise Price would be less than the then current par value of outstanding shares of Common Stock.

 

6.            Fractional
Shares. No fractional shares shall be issued upon the exercise
of this Warrant as a consequence of any adjustment pursuant hereto. All Exercise Shares (including fractions) to be issued upon
exercise of this Warrant shall be aggregated for purposes of determining whether the exercise would result in the issuance of any
fractional share. If, after aggregation, the exercise would result in the issuance of a fractional share, the Company shall, in
lieu of issuance of any fractional share, pay the Holder otherwise entitled to such fraction a sum in cash equal to the product
resulting from multiplying the then current fair market value of one Exercise Share by such fraction.

 

7.            Transfer
of Warrant. 

 

(a)          Transferability.
On or before the Voting Period End Date (as defined below), the Class D-2 Warrants shall not be directly or indirectly assignable
or transferable by the Holder, and the Holder shall not at any time, directly or indirectly, sell, assign, transfer or otherwise
dispose of, loan or pledge any Class D-2 Warrants or any economic or voting interests or rights associated therewith, except as
specifically authorized by the Board of Directors in its sole discretion. Any purported transfer or assignment in violation of
the foregoing shall be void ab initio and given no effect. After the Voting Period End Date, this Warrant and all rights hereunder
are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated
agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder
or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. “Voting
Period End Date” means the 80th day after the conclusion of the Company’s 2017 annual meeting of stockholders.
Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name
of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment,
and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly
be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant
to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the
Company within three (3) Business Days of the date on which the Holder delivers an assignment form to the Company assigning this
Warrant full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Exercise
Shares without having a new Warrant issued.

 

    	 	5	 

     

    

 

(b)          New
Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the
Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 7(a), as to any transfer which may be involved in such
division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants
to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the date
of the original issuance of the Warrant and shall be identical with this Warrant except as to the number of Exercise Shares issuable
pursuant thereto.

 

(c)          Warrant
Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant
Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered
Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and
for all other purposes, absent actual notice to the contrary.

 

8.             Lost,
Stolen, Mutilated or Destroyed Warrant. If this Warrant is lost,
stolen, mutilated or destroyed, the Company may, on such terms as to indemnification by the Holder or otherwise as it may reasonably
impose (which shall, in the case of a mutilated Warrant, include the surrender thereof), issue a replacement Warrant of the same
denomination and tenor as the Warrant so lost, stolen, mutilated or destroyed. Upon the issuance of any such replacement Warrant,
the original Warrant shall become null and void without the necessity of any further action on the part of the Company.

 

9.            Amendment.
Any term of this Warrant may be amended or waived only with the advance written consent of the Company and the Holder.

 

10.          Notices,
etc. All notices required or permitted hereunder shall be in writing
and shall be effective upon delivery to the recipient. All communications shall be sent to the Company and to the Holder at the
addresses listed on the signature page hereof or at such other address as the Company or Holder may designate by written notice
to the other parties hereto.

 

11.          Governing
Law. This Warrant and all rights, obligations and liabilities hereunder
shall be governed by and construed under the laws of the State of Delaware without giving effect to conflicts of laws principles.

 

[Signature Page Follows]

 

    	 	6	 

     

    

 

In
Witness Whereof, the Company has caused this Warrant to be executed by its duly authorized officer as of the date first
written above.

 

	 	Northwest Biotherapeutics, Inc.
	 	 	 
	 	By:	/s/ Leslie J. Goldman
	 	 	 
	 	Name:	Leslie J. Goldman
	 	 	 
	 	Title:	Senior Vice President
	 	 	 
	 	Address:	4800 Montgomery Lane
	 	 	Suite 800
	 	 	Bethesda, MD  20814

 

	 	ACKNOWLEDGED AND AGREED:	 
	 	 	 
	 	 	 
	 	 	 
	 	By:	                                 	 
	 	 	 	 
	 	Name: 	 	 

 

Signature
Page to Warrant 

 

     

     

    

 

NOTICE OF EXERCISE

 

TO: Northwest Biotherapeutics,
Inc.

 

(1)         The
undersigned hereby elects to purchase ________ shares of Common Stock (the “Exercise Shares”) of Northwest
Biotherapeutics, Inc. (the “Company”) pursuant to the terms of the attached Warrant, and tenders
herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

 ̈

(1)

 

The undersigned hereby
elects to purchase ________ shares of Common Stock (the “Exercise Shares”) of Northwest
Biotherapeutics, Inc. (the “Company”) pursuant to the terms of the net exercise provisions
set forth in Section 2.2 of the attached Warrant, and shall tender payment of all applicable transfer taxes, if any.

 ̈

 

(2)         Please
issue a certificate or certificates representing said Exercise Shares in the name of the undersigned or in such other name as is
specified below:

 

________________________

(Name)

 

________________________

________________________

(Address)

 

	 	 	 
	(Date)	 	(Signature)
	 	 	 
	 	 	 
	 	 	(Print name)

 

     

     

    

 

ASSIGNMENT FORM

 

(To assign the foregoing Warrant,
execute this form and supply required information. Do not use this form to purchase shares.)

 

For
Value Received, the foregoing Warrant and all rights evidenced thereby are hereby assigned to:

 

	Name:	 	 
	 	(Please Print)	 
	 	 	 
	Address:	 	 
	 	(Please Print)	 

 

Dated: __________, 20__

 

	Holder’s	 	 
	Signature:	 	 
	 	 	 
	Holder’s	 	 
	Address:	 	 

 

NOTE: The signature to this Assignment Form must correspond
with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatever. Officers of corporations
and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing
Warrant.Exhibit 10.2

 

VOTING AGREEMENT

 

This Voting Agreement (the “Agreement”)
is effective as of a ____________, 2017, and is by and between Northwest Biotherapeutics, Inc., a Delaware corporation (the
“Company”) and ____________, a ____________ (the “Investor”).

 

RECITALS

 

WHEREAS, the Company has established a class
of Series B Preferred Stock (the “Series B Preferred”) and the terms and conditions of such Series B Preferred
are set forth in a Certificate of Designations filed with the Delaware Secretary of State on or before the date of this Agreement,
a filed and certified copy of which has been provided to the Investor (the “Certificate of Designations”);

 

WHEREAS, concurrently herewith, the Investor
is entering into a Subscription Agreement (the “Subscription Agreement”) to purchase Series B Preferred and
certain warrants to acquire shares of the Common Stock of the Company from the Company (the “Class D-2 Warrants”
and, together with the Covered Shares and any other securities convertible into or exercisable for Common Stock, the “Equity
Securities”); and

 

WHEREAS, the Investor is entering into this
Agreement in accordance with the terms and conditions of the Subscription Agreement.

 

AGREEMENT

 

NOW, THEREFORE, in consideration of the foregoing
and the mutual covenants and agreements herein contained, and intending to be legally bound hereby, Company and the Investor hereby
agree as follows:

 

1.            Agreement
to Vote. During the term of this Agreement, the Investor agrees that for purposes of any shareholder meeting or action of any
kind, (a) the Investor will cause the Covered Shares (as defined in Section 6(e) hereof) to be counted as present for purposes
of establishing a quorum, and will respond to each request by the Company for written consent, if any, and (b) the Investor
will vote (or consent), or cause to be voted (or cause consent to be granted), all Covered Shares in accordance with the recommendations
of the Company’s Board of Directors with respect to any amendment to the Company’s certificate of incorporation as
the Board of Directors may deem necessary or appropriate to increase the Company’s authorized common stock and/or preferred
stock.

 

    	 	1	 

     

    

 

2.            Grant
of Proxy; Appointment of Proxy.

 

(a)          The Investor hereby grants to, and appoints,
the Company, the executive officers of the Company, and any other designee of the Company, such Investor’s irrevocable (until
the Termination Date) proxy and attorney-in-fact (with full power of substitution) to vote the Covered Shares as provided in Section 1.
The Investor intends this proxy to be unconditional and irrevocable (until the Termination Date) and coupled with an interest,
and will take such further action and/or execute such other instruments as may be necessary to effectuate the intent of this proxy,
and hereby represents to the Company that no other proxy has been or will be given during the term of this Agreement.

 

(b)          The proxy granted herein shall automatically
expire upon the expiration or termination of this Agreement.

 

3.            Term
and Termination. This Agreement shall terminate at the end of the Voting Period End Date (as such term is defined in the Certificate
of Designations) (the end of such date, the “Termination Date”).

 

4.            Representations
and Warranties of the Investor. The Investor hereby represents and warrants to the Company as follows:

 

(a)          The
Investor is the record owner and beneficial owner of the Covered Shares, free and clear of encumbrances. The Investor has sole
voting power, sole power of disposition and sole power to agree to all of the matters set forth in this Agreement, with respect
to all of the Covered Shares. The Covered Shares are not subject and during the term of this Agreement will not be subject to any
voting trust agreement, stock loan or other contract, promise, arrangement, obligation or commitment which may restrict or otherwise
affect the voting of the Covered Shares. The Investor has not appointed or granted any proxy or power of attorney with respect
to any Covered Shares to any party other than the Company as set forth in this Agreement. Execution, delivery and performance of
this Agreement by the Investor will not conflict with or result in any breach or violation of any contract, promise, arrangement,
obligation or commitment.

 

(b)          The
Investor is duly organized, validly existing and in good standing under the laws of the jurisdiction of its formation and has all
requisite power and authority to execute and deliver this Agreement and to perform its obligations hereunder. The execution, delivery
and performance of this Agreement by the Investor have been duly and validly authorized and no other actions or proceedings are
necessary to authorize the execution, delivery and performance of this Agreement by the Investor. Upon execution, this Agreement
will constitute a legal, valid and binding obligation of the Investor, enforceable against the Investor in accordance with its
terms, except as enforcement may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting
creditors’ rights generally and by general principles of equity (regardless of whether considered in a proceeding in equity
or at law).

 

    	 	2	 

     

    

 

5.            Representations, Warranties and Covenants
of the Company. The Company hereby represents, warrants and covenants to the Investor that: (a) the Company is duly organized,
validly existing and in good standing under the laws of the jurisdiction of its formation and has all requisite power and authority
to execute and deliver this Agreement and to perform its obligations hereunder; (b) the execution, delivery and performance of
this Agreement by the Company have been duly and validly authorized and no other actions or proceedings are necessary to authorize
the execution, delivery and performance of this Agreement by the Company; (c) upon execution, this Agreement will constitute a
legal, valid and binding obligation of the Company, enforceable in accordance with its terms, except as enforcement may be limited
by applicable laws relating to bankruptcy or insolvency, or similar laws affecting creditors’ rights.

 

6.            Investor
Covenants. The Investor hereby covenants and agrees as follows for the period from the date hereof through and including the
Termination Date:

 

(a)          The
Investor will not directly or indirectly enter into, cause, allow or accept any voting trust or other trust agreement, stock loan,
security interest, encumbrance, or other contract, promise, arrangement or commitment which may restrict, control or otherwise
affect the voting of the Covered Shares during the term of this Agreement.

 

(b)          The
Investor will not take any action that would make any representation or warranty of such Investor untrue or incorrect, or directly
or indirectly have the effect of preventing or disabling such Investor from performing its obligations under this Agreement.

 

(c)          The
Investor will not at any time directly or indirectly take, participate in, authorize, allow, accept or support any action or opposition
to action that may conflict with any shareholder vote or consent, or any action or matter approved by any shareholder vote or consent,
pursuant to this Agreement or to which this Agreement relates.

 

(d)          In
addition to any restrictions on transfer under applicable federal and state securities laws, the Investor will not sell (constructively
or otherwise), transfer, pledge, hypothecate, grant, encumber, assign or otherwise dispose of (collectively, “Transfer”),
or enter into any contract, option, agreement or other arrangement or understanding with respect to the Transfer of any of the
Equity Securities or beneficial ownership or voting power thereof or therein (including by operation of law), unless the transferee
or purchaser enters into this Voting Agreement. Any Transfer in violation of this provision shall be void. The Investor authorizes
the Company to notify the Company’s transfer agent that there is a stop transfer order with respect to all of the Equity
Securities and that this Agreement places limits on the voting of the Equity Securities.

 

(e)          For
purposes of this Agreement, the “Covered Shares” shall include all shares of Common Stock and shares of the Company’s
preferred stock owned of record or beneficially by the Investor, or as to which the Investor otherwise has the power to vote or
direct the voting of or has a voting interest in, as of the date of this Agreement or as to which the Investor acquires such ownership
or beneficial or other interest during the term of this Agreement.

 

    	 	3	 

     

    

 

7.            Further Assurances. The Investor shall
take such further action as may be reasonably requested by the Company, from time to time, to consummate and make effective the
performance of this Agreement in accordance with its terms.

 

8.            Miscellaneous.

 

(a)          Amendments. This Agreement may not
be amended, modified or supplemented in any manner, whether by course of conduct or otherwise, except by an instrument in writing
signed by both parties.

 

(b)          No Waiver. No failure or delay of
any party in exercising any right or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise
of any such right or power, or any abandonment or discontinuance of steps to enforce such right or power, or any course of conduct,
preclude any other or further exercise thereof or the exercise of any other right or power. The rights and remedies of the parties
hereunder are cumulative and are not exclusive of any rights or remedies which they would otherwise have hereunder. Any agreement
on the part of a party to any such waiver shall be valid only if set forth in a written instrument executed and delivered by such
party.

 

(c)          Notices. All notices and other communications
hereunder shall be effective upon delivery, shall be in writing and shall be deemed duly given if delivered (a) personally,
or by facsimile or e-mail, upon written confirmation of receipt by facsimile or e-mail, (b) by next-day courier service by
a nationally recognized courier company or (c) by registered or certified mail, return receipt requested, postage prepaid.

 

(d)          Entire Agreement. This Agreement,
the Subscription Agreement and the Certificate of Designations constitute the entire agreement between the parties relating to
the subject matter hereof, and supersede all prior written agreements, arrangements, communications and understandings and all
prior and contemporaneous oral agreements, arrangements, communications and understandings between the parties.

 

(e)          Assignment; Successors. Neither this
Agreement nor any of the rights, interests or obligations under this Agreement may be assigned or delegated, in whole or in part,
by operation of law or otherwise, by either party without the prior written consent of the other party, and any such assignment
without such prior written consent shall be null and void. This Agreement will be binding upon and inure to the benefit of the
parties and their successors and assigns.

 

(f)           Specific Performance. The parties
agree that irreparable damage would occur in the event that any provisions of this Agreement were not performed in accordance with
their terms or were otherwise breached, and that money damages would not be adequate. Accordingly, the Company will be entitled
to specific performance of this Agreement and the obligations of the Investor hereunder, including injunctions to prevent breaches
of this Agreement and to enforce the terms and provisions of this Agreement.

 

(g)          Governing Law and Dispute Resolution.
This Agreement and all disputes or controversies arising out of or relating to this Agreement or the transactions contemplated
hereby shall be governed by, and construed in accordance with, the internal laws of the State of Delaware, without regard to choice
of law provisions, and in the courts located in the State of Delaware. Each party waives all right to a trial by jury in any action,
proceeding or counterclaim arising out of or relating to this Agreement or the transactions contemplated hereby.

 

    	 	4	 

     

    

 

(h)          Severability. Whenever possible,
each provision or portion of any provision of this Agreement shall be interpreted in such manner as to be effective and valid under
applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any
applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any provision in such
jurisdiction, and this Agreement shall be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or
unenforceable provision had never been contained herein.

 

(i)            Counterparts. This Agreement may
be executed in two or more counterparts, all of which shall be considered one and the same instrument and shall become effective
when one or more counterparts have been signed by each of the parties and delivered to the other party.

 

(j)            Facsimile or .pdf Signature. This Agreement may be executed by facsimile or .pdf signature and a facsimile or .pdf
signature shall constitute an original for all purposes.

 

(k)           No Presumption Against Drafting Party.
Each of the parties to this Agreement has been represented by counsel in connection with this Agreement and the transactions contemplated
herein. The interpretation and enforcement of this Agreement shall not be affected by any presumption against the drafting party,
or any similar rule or principle.

 

[The remainder of this page is intentionally
left blank.]

 

    	 	5	 

     

    

 

IN WITNESS WHEREOF, the Investor and the Company
have executed this Agreement as of the date first written above.

 

	 	[INVESTOR]
	 	 
	 	 
	 	Name:  
	 	Title:
	 	 
	 	NORTHWEST BIOTHERAPEUTICS, INC.
	 	 
	 	/s/ Leslie J. Goldman
	 	Name: Leslie J. Goldman  
	 	Title: Senior Vice President

 

[Signature Page to Voting Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00278-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00278-of-00352.parquet"}]]